SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are drawing attention after rising sharply despite a Q3 revenue and EPS miss, with traders focusing instead on premium subscriber growth, stronger gross margin, and an upbeat Q4 operating-income outlook. The move has surprised skeptics, while bullish traders point to the guidance and operating metrics as support for the rally.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional push, including its institutional-market launch, new leadership, and plans tied to tokenized assets and DeFi. Traders see these developments as potential growth drivers, while others remain frustrated that COMP has lagged broader crypto and struggled to sustain gains.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by growth in Dupixent and Eylea HD, is driving a sharp share-price gain and breakout discussion. Traders are broadly bullish on the follow-through and new highs, while some are watching for a pullback or gap retest.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHDs strong performance and fresh highs are drawing attention as traders describe a rotation from volatile tech and AI stocks into dividend-paying value funds for defensive exposure. Long-term holders are celebrating and adding shares, while some caution the rally may be stretched and note that rising Treasury yields can pressure dividend ETFs.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

IBKR is drawing attention after its earnings report prompted a selloff despite growth in client accounts and interest income; traders are focused on weaker trading activity and competition, while others view the firms profitability and dividend increase as positives. The reaction reflects debate over whether slower activity outweighs the companys strong underlying business.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put pressure on Precigens PAPZIMEOS and sparked debate over how much competition it will bring. Traders weigh Inovios potential treatment advantages against Precigens commercial head start and full-approval status, while questioning the rivals accelerated-approval and commercialization path.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Shares are under pressure after Schwabs Q3 revenue fell slightly short of estimates despite an earnings beat, with traders focused on whether the prolonged decline can hold near $84. Some see an oversold buying opportunity, while others remain concerned about continued weakness and recurring platform outages.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVies stronger-than-expected third-quarter results and raised 2026 outlook, supported by growth in its immunology portfolio, are driving attention. Traders are weighing the earnings beat against the stocks recent run-up, with some cheering the results and others describing the reaction as profit-taking or sell the news.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

A broader market and technology-stock selloff is weighing on QQQI, prompting many income-focused traders to buy the dip while others are moving to cash or questioning the funds downside and NAV risks. The discussion also centers on its monthly option-income distributions and the trade-off between cash flow and capped upside.

Carpenter Technology Corp. engages in the manufacturing, fabrication, and distribution of specialty metals. It operates through the Specialty Alloys Operations and Performance Engineered Products segments. The Specialty Alloys Operations segment is composed of its major premium alloy and stainless-steel manufacturing operations. The Performance Engineered Products segment includes the Dynamet titanium, Carpenter Additive, and the Latrobe and Mexico distribution businesses. The company was founded by James Carpenter in 1889 and is headquartered in Philadelphia, PA.

Carpenter Technology Corp.

Carpenter Technologys latest quarterly report has sparked a sharp selloff despite profit coming in above expectations: revenue missed, the full-year outlook was maintained, and higher capital spending weighed on free cash flow. Bulls call the drop an oversold reaction to strong aerospace and defense demand, while bears focus on the cautious outlook and cash-flow pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizers move through the long-watched $30 level and fresh 52-week highs has traders focused on momentum ahead of its quarterly report, with some pointing to defensive-sector rotation and recent oncology approvals, including the expanded TUKYSA use. The reaction is divided between optimism about the breakout and concern that earnings expectations, patent expirations, and Pfizers history of range-bound trading could limit follow-through.

Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?

Key PointsPfizer shares are up amid bullish sentiment about the pharmaceutical company's turnaround efforts...

From Cancer Breakthroughs to a Potential Short Squeeze: Stocks Investors Should Watch

From promising cancer trial results from Pfizer (NYSE: PFE) to groundbreaking brain cancer research at NeOnc Technologies Holdings (NASDAQ:NTHI) and electric vehicle momentum at Rivian Automotive (NASDAQ:RIVN) to consumer healthcare challenges at Haleon (NYSE:HLN), major offshore contract wins at Transocean (NYSE:RIG) and impressive financial results at Rocket Companies (NYSE:RKT), these companies are delivering developments worth watching. Add agricultural innovation from Corteva (NYSE:CTVA), and an $18 million vessel transaction at AI OKTO (NASDAQ: AIOK), investors have plenty of reasons to keep these companies on their radar.

HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.

Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of +17.45% and +4.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.

Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.

Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?

Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.

This account has been verified as an official PFE representative.

Verified Account

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>CEO Angelos Stergiou marked Sellas’ 15th anniversary, pointing to its “next chapter” with GPS and SLS009.</li><li>Retail investors floated $40 billion-$120 billion valuation scenarios and share-price predictions ranging from $100 to $540.&nbsp;</li><li>Investors await Regal’s final-analysis trigger of 80 deaths, following Sellas’ disclosure of 78 events as of May 11.</li></ul>Retail investors in Sellas Life Sciences (SLS) are floating multibillion-dollar buyout scenarios and steep share-price gains after CEO Angelos Stergiou marked the company’s 15th anniversary with a post about its “next chapter.”<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 5% on Monday to $10.49, snapping three straight losing sessions.&nbsp;<h2 class="st-heading-2">Sellas CEO Points To ‘Best Chapters’ Ahead</h2>In his LinkedIn post, Stergiou reflected on Sellas’ growth from a private startup into a public biotech advancing investigational cancer treatments GPS and SLS009.“Reaching 15 years isn't just about celebrating our history; it is about stepping into our next chapter with even greater focus, drive, and resolve,” he said. He acknowledged past setbacks and thanked shareholders, employees and trial participants, while reaffirming the company’s commitment to patients.“Our mission remains deeply personal, and our promise to the patients we aim to serve is steadfast. We look forward, God willing, to the best chapters that are still to be written with GPS and SLS009,” he added.<h2 class="st-heading-2">SLS Retail Floats Multibillion-Dollar Buyout Scenarios</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 258% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_725c1f1d42.png" alt="sls ss.png" width="633" height="343"><figcaption>SLS sentiment and message volume as of October 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Reformed_MMAT_investor/message/666881029">said</a>: “My opinion, Dr. Stergiou’s message was a master-class at reassuring EVERYONE that all is well.”A user<a href="https://stocktwits.com/Gebinator/message/666869438"> also&nbsp;floated</a> a minimum $40 billion valuation. Another user<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/666882686">&nbsp;argued</a> for a $50 billion valuation, calling a $247-per-share figure. A separate user<a href="https://stocktwits.com/vlucky16/message/666866929">&nbsp;proposed</a> a $120 billion buyout scenario and also predicted a share price of $540-plus.Across bullish share-price predictions, including scenarios tied to clinical results, targets ranged from $100 to over $540. Discussing buyout news in case of favorable data, one user&nbsp;<a href="https://stocktwits.com/AIALuckyDog/message/666879536">said</a>: “If BO news post good data then there’s no stopping this beast (really no explanation required as it could go full berserker mode).” BO means buyout.Another user challenged the lofty valuations and&nbsp;<a href="https://stocktwits.com/noviceEve/message/666855368">said</a>: “I will be so glad to get out of this ticker when it hits $15 again.”<h2 class="st-heading-2">Retail Searches Filings, Conference Plans For Clues</h2>The CEO’s message comes as investors have been&nbsp;searching for potential deal signals in recent months. In June, a filing disclosed changes to executive severance arrangements, including lump-sum payment provisions for Stergiou.For CFO John Burns and chief development officer Dragan Cicic, qualifying departures within one month before or one year after a change of control would trigger 15 months of salary, the annual target bonus, up to 18 months of health-coverage reimbursements and full vesting of unvested equity.&nbsp;Sellas’ conference plans have provided another talking point. The company is listed at Booth 138, with a 20-by-30-foot space, for the Dec.12- Dec.15 American Society of Hematology (ASH) meeting in New Orleans. Major exhibitors include Eli Lilly, Pfizer, Merck, AbbVie and Bristol Myers Squibb. The booth size has fueled speculation about a partnership or acquisition.<h2 class="st-heading-2">Sellas Regal Trial And SLS009 Data In Focus</h2>Currently, investors are awaiting data from Sellas’ two lead programs. The Phase 3 Regal trial is testing GPS, an immunotherapy targeting WT1, in acute myeloid leukemia (AML) patients who achieved a second complete remission following salvage treatment. Its final-analysis process is triggered by 80 deaths. Sellas reported 78 events as of May 11. Reaching 80 precedes database lock, data review and analysis before results are disclosed.&nbsp;The company also expects fourth-quarter topline data from its 80-patient Phase 2 SLS009 study in newly diagnosed AML, including patients with early resistance to azacitidine and venetoclax. SLS009 is also being explored in pancreatic cancer. Preclinical findings from last month showed 17.9% apoptosis (programmed cell death) in a patient-derived tumor model resistant to Daraxonrasib, versus 2.8% with Daraxonrasib alone. Combining the drugs raised apoptosis to 36.5% and necrosis to 30.6%.&nbsp;SLS stock has surged 178% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avgo-stock-10-year-docomo-deal-retail-on-edge-ceo-ai-casino-remarks/cZxqiudRBuJ">AVGO Stock Edges Up Overnight After 10-Year Docomo Deal, But Retail Stays On Edge Over CEO’s AI ‘Casino’ Remarks&nbsp;</a>

Representative Image (Photo credit: Getty Images)

Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Bristol-Myers Squibb Co.

Lilly(Eli) & Co

Merck & Co Inc

Pfizer Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Track PFE stock price, charts, news and real-time market activity on Stocktwits. Join the PFE message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Pfizer Inc stock.

PFE Stock Price Today - Pfizer Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

PFE Futures

PFE Single Stock Futures

PFE Micro Single Stock Futures